Read now


Discover the conference highlights

Acceptance of risks associated with disease modifying therapies in multiple sclerosis


  • Kidney injury and progressive multifocal leukoencephalopathy (PML) are the most important concerns for people with multiple sclerosis (MS) when selecting disease modifying therapy (DMT), and men, older individuals, those with higher disability levels and current DMT users are more willing to accept higher levels of DMT-associated risk.

Why this matters

  • Understanding treatment preferences of individuals with MS is a critical aspect of shared decision making, which might lead to improved treatment satisfaction, therapy adherence and clinical outcomes.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.